Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of...
Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease NEW YORK, April 12, 2022 /PRNewswire/ -- Hoth...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments,...
Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft...